From Dr. Google to Dr. ChatGPT: Evaluating the Credibility of ChatGPT for Pulmonary Arterial Hypertension Information

Patients worldwide are increasingly switching from Dr. Google to Dr. Chat GPT. A recent article titled “Trustworthiness, Value, Danger, and Readability of ChatGPT-Generated Responses to Health Questions Related to Pulmonary Arterial Hypertension”, published in the Cureus Journal of Medical Science on October 14, 2024, aimed to determine how well ChatGPT could accurately and consistently respond […]

From Dr. Google to Dr. ChatGPT: Evaluating the Credibility of ChatGPT for Pulmonary Arterial Hypertension Information Read Post »

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States, Pharmacoeconomics, October 12, 2024

A study published on Pharmacoeconomics on October 12 reveals that pulmonary arterial hypertension continues to be associated with a very high economic burden and healthcare resource utilization across all payer types within the US healthcare system. The study included 11,670 patients enrolled in Medicare Fee-for-Service, 1,021 patients enrolled in Medicare Advantage, 274 patients enrolled in

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States, Pharmacoeconomics, October 12, 2024 Read Post »

“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation , October 4, 2024: a state-of-the-art review which summarizes the current understanding of the mechanism of action of sotatercept, the impact on outcomes that improve how patients feel, function, and survive, and the safety and

“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024 Read Post »

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024

A new study published in Acta cardiologica on October 4, 2024, reviews the current evidence on sotatercept and provides a Belgian perspective on its place in the future treatment strategy for pulmonary arterial hypertension. We are delighted to see that two patients from Belgium are included as co-authors. Wendy Vansteenkiste is the President of the

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024 Read Post »

Beyond Provision: A Multidimensional View of Access to Health Care for Rare Diseases, The Lancet Global Health, October 2024

Access to health care is a broad and complex topic that warrants a clearer definition. What does is actually mean? Is it simply the provision of health services and medicines? An article titled “Access in the rare diseases landscape”, published in The Lancet Global Health October 2024 edition, delves into the different aspects that define

Beyond Provision: A Multidimensional View of Access to Health Care for Rare Diseases, The Lancet Global Health, October 2024 Read Post »

The European Lung Foundation (ELF)’s 2023 Annual Report highlights its ongoing efforts to to collaborate with patients, patient organisations, healthcare professionals and the public

The Alliance for Pulmonary Hypertension is a proud member of the European Lung Foundation (ELF) Patient Organisation Network and is represented in the European Lung Foundation Pulmonary Hypertension Patient Advisory Group (PH PAG). The European Lung Foundation Patient Advisory Groups and working groups are made up of people who have an interest in a particular

The European Lung Foundation (ELF)’s 2023 Annual Report highlights its ongoing efforts to to collaborate with patients, patient organisations, healthcare professionals and the public Read Post »

“Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus”, Vascular Pharmacology, September 10, 2024

Abstract “Despite the innovations introduced in the 2022 European Society of Cardiology/European Respiratory Society Guidelines on Pulmonary Hypertension, risk discrimination and management of pulmonary arterial hypertension patients at intermediate risk still represents a grey zone. Additionally, clinical evidence derived from currently available studies is limited. This expert panel survey intends to aid physicians in choosing

“Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus”, Vascular Pharmacology, September 10, 2024 Read Post »

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024

The full proceedings of the World Symposium on Pulmonary Hypertension which was held in Barcelona 29.6-1.7, 2024, have now been published in the European Respiratory Journal at this link. The proceedings cover the work of the 15 task forces; Task Force n°1’s article is titled “Exploring the patient perspective in pulmonary hypertension” (see below for

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024 Read Post »

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH)

The CLARITY survey, the findings of which were published in the Pulmonary Circulation April 2024 issue (link), aimed to collect data on current chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis, treatment, and management, and to identify unmet medical needs. Conducted from September 2021 to May 2022, the survey targeted hospital-based medical specialists via Scientific Societies and

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH) Read Post »

Patients as teachers? A pilot experiment of patient-led online learning modules for HCPs in Canada proves the effectiveness of this approach, “BMC Medical Education”, May 10, 2024

A study titled “Patients as teachers: a within-subjects randomized pilot experiment of patient-led online learning modules for health professionals” was published on BMC Education on May 10, 2024. Medical education programs are increasingly including presentations by individuals with lived experiences. The authors of the article say that relying on a limited number of speakers may

Patients as teachers? A pilot experiment of patient-led online learning modules for HCPs in Canada proves the effectiveness of this approach, “BMC Medical Education”, May 10, 2024 Read Post »

April 28 is ESOT, European Society for Organ Transplantation, Action Day, an annual observance which calls for enhanced cooperation between EU member states to address inequalities in transplantation

April 28 is ESOT – European Society for Organ Transplantation Action Day. ESOT is calling for enhanced cooperation among EU member states to empower transplant centres in delivering consistent, high-quality transplantation service ahead of the EU elections. ESOT is looking to drive the following 5 actions in the European Parliament between 2024 and 2029: Read

April 28 is ESOT, European Society for Organ Transplantation, Action Day, an annual observance which calls for enhanced cooperation between EU member states to address inequalities in transplantation Read Post »

Launched today, Rare Disease Day 2024, the PHA Europe “BEL AIR” virtual conference center for pulmonary hypertension

The BEL AIR CENTER is a virtual conference center, divided into several “rooms” where visitors can find and view presentations from leading pulmonary hypertension experts and from PHA Europe’s industry partners, patient association information booths, an art gallery with works by patients and health care professionals, and a networking café. Prof. Marc Humbert, Director of

Launched today, Rare Disease Day 2024, the PHA Europe “BEL AIR” virtual conference center for pulmonary hypertension Read Post »

“EXPOSURE” study provides insights into real-world management and outcomes of patients with pulmonary arterial hypertension -“Advances in Therapy”, January 13,2024

“EXPOSURE” (EUPAS19085) is an observational study describing the characteristics, treatment patterns, and outcomes of patients with pulmonary arterial hypertension initiating a new specific therapy in Europe/Canada. In total, 1.944 patients with follow-up information were included. Most study patients were female with WHO functional class II/III symptoms and idiopathic or connective tissue disorder-associated pulmonary arterial hypertension.

“EXPOSURE” study provides insights into real-world management and outcomes of patients with pulmonary arterial hypertension -“Advances in Therapy”, January 13,2024 Read Post »

“Pulmonary arterial hypertension and COVID-19: piecing the puzzle”, Respiratory Medicine and Research, November 2023

A recent article titled “Pulmonary arterial hypertension and COVID-19: piecing the puzzle”, published in Respiratory Medicine and Research, summarises the existing literature on the clinical presentation of COVID-19 in patients with pulmonary arterial hypertension, focusing on shared pathobiology, clinical outcomes, potential treatment strategies, and the need for further research in understanding and managing these conditions.

“Pulmonary arterial hypertension and COVID-19: piecing the puzzle”, Respiratory Medicine and Research, November 2023 Read Post »

Artificial intelligence could help restore the essential humaneness in medicine by providing the gift of time, The Lancet, October 21, 2023

In the age of artificial intelligence, chat bots and automated services, our quest for empathy becomes more pressing than ever. Counterintuitively, Dr. Eric J. Topal, an American cardiologist, scientist, and best selling author, claims that artificial intelligence has the potential to enhance empathy, particularly in the vital relationship between patients and clinicians. In a recent

Artificial intelligence could help restore the essential humaneness in medicine by providing the gift of time, The Lancet, October 21, 2023 Read Post »

Findings from a decade-long study, published in the August 2023 edition of “Transplant International”, offer promise for a significant surge in the availability of lungs for transplant

A study titled “Cytokines Removal During Ex-Vivo Lung Perfusion: Initial Clinical Experience”, by researchers Boffini et al. was published in August 2023 in Transplant International. Covering a period of 10 years, from 2011 to 2020, research by has demonstrated for the first time – on an unparalleled large case series of 54 lung treatments intended

Findings from a decade-long study, published in the August 2023 edition of “Transplant International”, offer promise for a significant surge in the availability of lungs for transplant Read Post »

Patient Perspectives in the French RHU DESTINATION 2024 project on Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Management

RHU DESTINATION 2024 is a hospital and university research funded by the French government. It is led by Prof. Marc Humbert, Director of the French National Pulmonary Hypertension Reference Centre, and coordinated by the Assistance Publique-Hôpitaux de Paris (Bicêtre Hospital). Partners include the University of Paris-Saclay, Inserm, Marie Lannelongue Hospital, as well as three private

Patient Perspectives in the French RHU DESTINATION 2024 project on Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Management Read Post »

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages

Did you know that the lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages: English, French, German, Greek, Italian, Polish, Portuguese (Portugal), Russian, Spanish, Romanian, Ukrainian. The English version of the lay summary was developed with the active collaboration of the two

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages Read Post »

Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate!

📣 Yesterday, August 14 2023, the The Lancet published a ground-breaking three-paper series on pulmonary hypertension. 1️⃣ In the first paper, Prof. Marc Humbert and colleagues provide an overview of the pathophysiology of pulmonary arterial hypertension, current therapeutic approaches, and emerging treatment options, with a forward-looking discussion of innovative solutions for future clinical trials. We

Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate! Read Post »

TRANSLATE »
Scroll to Top